Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02337062
Recruitment Status : Completed
First Posted : January 13, 2015
Results First Posted : August 4, 2017
Last Update Posted : March 20, 2019
Sponsor:
Information provided by (Responsible Party):
Acacia Pharma Ltd

Brief Summary:
A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).

Condition or disease Intervention/treatment Phase
PONV Drug: APD421 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1147 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients
Study Start Date : February 2015
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: APD421 + standard anti-emetic
Single dose of IV APD421
Drug: APD421
Placebo Comparator: Placebo + standard anti-emetic
Single dose of IV placebo
Drug: Placebo



Primary Outcome Measures :
  1. Number of Participants With Complete Response [ Time Frame: 24 hours after the end of surgery ]
    Complete response defined as no emesis and no use of rescue medication in the 24 hour period after end of surgery (defined as wound closure)


Secondary Outcome Measures :
  1. Number of Participants With Emesis [ Time Frame: 24 hours after the end of surgery ]
    Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)

  2. Number of Participants Receiving Rescue Medication [ Time Frame: 24 hours after the end of surgery ]
    Rescue medication defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or emesis, or any incidental use of a drug known to have antiemetic potential

  3. Number of Participants With Any Nausea [ Time Frame: 24 hours after the end of surgery ]
    Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. "Any nausea" means a score ≥ 1.

  4. Number of Participants With Significant Nausea [ Time Frame: 24 hours after end of surgery ]
    Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. "Significant nausea" means a score ≥ 4.

  5. Time to First Violation of Criteria for PONV [ Time Frame: 24 hours after end of surgery ]
    Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients ≥ 18 years of age
  • Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure
  • Patients with at least 3 "Apfel" risk factors for PONV

Exclusion Criteria:

  • Patients scheduled to undergo transplant surgery
  • Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block
  • Patients who are expected to remain ventilated for a period after surgery
  • Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02337062


Locations
Show Show 25 study locations
Sponsors and Collaborators
Acacia Pharma Ltd
Investigators
Layout table for investigator information
Principal Investigator: Peter Kranke, MD Würzburg University Hospitals
Layout table for additonal information
Responsible Party: Acacia Pharma Ltd
ClinicalTrials.gov Identifier: NCT02337062    
Other Study ID Numbers: DP10017
First Posted: January 13, 2015    Key Record Dates
Results First Posted: August 4, 2017
Last Update Posted: March 20, 2019
Last Verified: March 2019